Based on preclinical evidence showing that intrathecally administered idursulfase can penetrate into brain tissue [13], a formulation of idursulfase for intrathecal (IT) administration (idursulfase-IT) has been investigated for the treatment of neuronopathic MPS II. This evidence concerns the gene IDS and mucopolysaccharidosis type 2.